Home
>
US Stocks
>
Rigel Pharmaceuticals
Rigel Pharmaceuticals
RIGL

Rigel Pharmaceuticals (RIGL)

$3.261.56%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$3.25
Today Low/High$3.25 / $3.34
52 Week Low/High$2.36 / $5.5
P/E ratio-70.8
Market Cap$548.43M

Company Details

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.
OrganisationRigel Pharmaceuticals
HeadquatersSouth San Francisco, California, US
Employees169
IndustryHealth Technology
CEORaul Rodriguez

Discover more

Frequently Asked Questions

What is Rigel Pharmaceuticals (RIGL) share price today?

Can Indians buy Rigel Pharmaceuticals (RIGL) shares?

How can I buy Rigel Pharmaceuticals (RIGL) shares from India?

Can Fractional shares of Rigel Pharmaceuticals (RIGL) be purchased?

What are the documents required to start investing in Rigel Pharmaceuticals (RIGL) stocks?

We are a SEBI registered investement advisor